This time, when Donald Trump hosted an event with two Big Pharma CEOs, the topic wasn’t drug pricing: it was jobs in American manufacturing, tied to a new, stronger glass vial. But it also looks like an early case study in effective engagement with an unpredictable White House.
It is very easy to dismiss the July 20 White House “Made in America Week” showcase for a shatterproof-glass vial venture among Merck, Pfizer and Corning as a simple publicity stunt.
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Cellares’ fully automated cell therapy manufacturing platform is the first system to receive an Advanced Manufacturing Technology designation from US FDA
The rollout of Trump’s plan has been a policy whiplash, but despite a 90-day pause on tariffs, the US president still appears to be holding a grudge with industry over drug pricing.
US-based Colossal Labs has claimed to bring back the dire wolf from extinction. While the science is not as dramatic in India yet, cell and gene therapies are making progress as treatments for cancer and other diseases. Pink Sheet takes a look at what is driving CGT success and growth.
The US FDA has deemed certain in vitro bioequivalence studies conducted by CRO Raptim Research “not acceptable” and raised concerns over its in vivo study methods.
The US FDA has deemed certain in vitro bioequivalence studies conducted by CRO Raptim Research “not acceptable” and raised concerns over its in vivo study methods.
Sector-specific tariffs, including on pharmaceuticals, could be announced as early as this week.
Faced with Trump’s hostile tariff moves, the UK aims to speed up clinical trial start times to support its pharma sector and invest £600m in a new health data research service.
